debt_leverage_profile
Near-zero debt; pre-revenue clinical-stage biotech funded primarily by equity raises; minimal interest-bearing liabilities on balance sheet.
Inferred
Agent_Inference
interest_rate_sensitivity
Negligible direct sensitivity; no material floating-rate debt. Higher rates increase cost of future equity dilution and reduce biotech risk appetite in capital markets.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) API/biological raw materials sourced via North American/EU CDMO networks; 2) Active pharmaceutical ingredient synthesis dependent on limited specialty chemical suppliers.
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; CAD/USD exposure from Canadian-domiciled operations. No material sovereign currency devaluation risk in top revenue markets currently.
Inferred
Agent_Inference
geographic_footprint
Primarily Canada and USA operations; negligible emerging-market revenue exposure; currency risk limited to CAD/USD fluctuation.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single or few CDMOs for clinical-stage drug manufacturing; substitution is possible but costly and time-consuming given regulatory revalidation requirements.
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage drug development; no cloud-infrastructure-dependent commercial product; AWS/GCP/Azure termination would disrupt internal ops minimally, not core value delivery.
Inferred
Agent_Inference
business_model_type_secondary
Secondary model is partnership/licensing; cloud termination would not materially impair partnering or licensing activities; data migration feasible within 60–90 days.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company uses standard scientific and business software. Core IP is proprietary biologics/therapeutics, not software platform integrations.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is drug development/licensing, not investment-contract-based. Common enterprise equity structure; no token or profit-sharing mechanism flagged.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure from clinical trial patient data; must comply with ICH GCP, PIPEDA, and EMA guidelines; data sovereignty obligations tied to trial jurisdictions.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; small-cap pre-revenue biotech with no dominant market position; no pricing power in commercial markets yet; no M&A activity triggering HSR review.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~0% recurring commercial revenue currently; 100% transactional via grants, licensing milestones, and equity financing; no subscription or multi-year commercial contracts.
Inferred
Agent_Inference
monetization_vector
Milestone-based licensing and potential royalty streams upon commercialization; near-term monetization via partnership deals and non-dilutive grant funding.
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture established; future pricing will be value-based for specialty dermatology/inflammatory indications, benchmarked against biologic competitors (~$15K–$40K/year).
Inferred
Agent_Inference
pricing_power_rating
Moderate potential pricing power if lead asset achieves differentiated efficacy/safety profile; subject to formulary negotiation and payer pushback in specialty drug market.
Inferred
Agent_Inference
target_gross_margin_bracket
Biotech royalty/licensing gross margins typically 80–95%; manufactured drug gross margins 60–80% post-commercialization; current stage generates no product gross margin.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; IP is patent-protected; clinical assets not subject to open-access exploitation; partnership agreements include exclusivity provisions.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear at scale; drug development is IP and partnership-driven. Commercialization could be outsourced via co-promotion; doubling revenue does not require doubling staff.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of revenue growth is low post-approval; incremental licensing royalties carry near-zero marginal cost; clinical trial costs are sunk or milestone-triggered.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Edesa Biotech does not operate a franchise network.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains low (B2B licensing to pharma partners); unit economics improve dramatically as fixed R&D costs are amortized over larger royalty/milestone base.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value derives from proprietary IP and clinical data, not user network scale. Durability of competitive moat depends on patent life and data exclusivity.
Inferred
Agent_Inference
asset_efficiency_ratio
-53.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; clinical-stage funding dependent on biotech capital market sentiment, which is recession-sensitive; approved drugs in inflammatory/derm indications show inelastic demand.
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical and biotech licensing partners (B2B); small number of potential acquirers/licensees creates high customer concentration risk at current stage.
Inferred
Agent_Inference
customer_segment_secondary
Grant-funding bodies (NIH, BARDA, Canadian government agencies); diversifies revenue source but each grant is non-recurring and competitive.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital is allocated toward clinical trial progression (future-state); no legacy physical infrastructure to maintain. CapEx is effectively R&D spend outsourced to CROs and CDMOs.
Inferred
Agent_Inference
sec_cik
0001540159
High
SEC-EDGAR
ticker
EDSA
High
SEC-EDGAR